Page last updated: 2024-08-24

epigallocatechin gallate and alpha-synuclein

epigallocatechin gallate has been researched along with alpha-synuclein in 42 studies

Research

Studies (42)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (9.52)	29.6817
2010's	29 (69.05)	24.3611
2020's	9 (21.43)	2.80

Authors

Authors	Studies
Mandel, S; Maor, G; Youdim, MB	1
Duhamel, H; Griffioen, G; Pannecouque, C; Pellens, K; Van Damme, N; van Leuven, F; Wera, S; Winderickx, J; Zabrocki, P	1
Bieschke, J; Boeddrich, A; Ehrnhoefer, DE; Engemann, S; Herbst, M; Lurz, R; Masino, L; Pastore, A; Wanker, EE	1
Roberts, BE; Shorter, J	1
Emmer, KL; Giasson, BI; Waxman, EA	1
Bieschke, J; Ehrnhoefer, DE; Friedrich, RP; Neugebauer, K; Russ, J; Wanker, EE; Wobst, H	1
Abedini, A; Meng, F; Plesner, A; Raleigh, DP; Verchere, CB	1
Bae, SY; Hwang, H; Kim, HK; Kim, JH; Kim, S; Kim, TD; Lee, S; Yoon, HC	1
Bieschke, J; Frank, RF; Grelle, G; Lorenz, M; Otto, A; Wanker, EE	1
Ikebukuro, K; Kerman, K; Kim, J; Kobayashi, N; Sasaki, Y; Sode, K; Veloso, AJ; Yoshida, W	1
Andersen, CB; Betzer, C; Christiansen, G; Jensen, PH; Kaspersen, JD; Lorenzen, N; Mulder, FA; Nielsen, SB; Otzen, DE; Pedersen, JS; Vad, BS; Yoshimura, Y	1
Brown, WT; Meeker, HC; Ramakrishna, N	1
Aelvoet, SA; Baekelandt, V; Debyser, Z; Gijsbers, R; Ibrahimi, A; Macchi, F; Van den Haute, C	1
Chan, P; Chen, M; Li, X; Li, Y; Wang, P; Wang, T; Yu, S; Yue, F	1
Cheng, XR; Kerman, K; Lagugné-Labarthet, F; Wallace, GQ	1
Caruana, M; Vassallo, N	1
Braun, D; Buell, AK; Dobson, CM; Genst, ED; Herling, TW; Knowles, TP; Mittag, JJ; Wolff, M	1
Dai, R; Guo, J; McGeer, PL; Qing, H; Quan, Z; Wong, W; Xu, Y; Yang, Q; Zhang, R; Zhang, Y	1
Grandori, R; Konijnenberg, A; Legname, G; Narkiewicz, J; Natalello, A; Ranica, S; Sobott, F	1
Brites, D; Brito, MA; Kim, KS; Palmela, I; Pirc, K; Pogačnik, L; Silva, RF; Skrt, M; Ulrih, NP	1
Baumgart, T; Canyurt, M; Cleveland, CL; Daniels, MJ; Haney, CM; Ischiropoulos, H; Owei, L; Petersson, EJ; Robustelli, J; Rodriguez, P; Wissner, RF	1
Batra, R; Chowdhury, PK; Gautam, S; Karmakar, S; Kundu, B; Pradhan, P; Sharma, P; Singh, J	1
de Moraes, MC; Fernandes, L; Foguel, D; Grimster, NP; Kelly, JW; Magalhães, AV; Moraes, N; Palhano, FL; Romão, L; Sagrillo, FS	1
Bai, Q; Liu, H; Liu, X; Shi, D; Yao, X; Zhou, S	1
Chen, C; Ding, Y; Liang, Q; Sun, Q; Xu, L; Zhang, Y; Zhao, J; Zhou, P	1
Ghosh, D; Jha, NN; Kumar, A; Kumar, R; Maji, SK; Mondal, M; Navalkar, A; Panigrahi, R; Sahay, S	1
Bhak, G; Lee, JT; Lee, S; Paik, SR; Park, JH; Rhoo, KY; Yang, JE	1
De Simone, A; Dobson, CM; Fusco, G; Ruggeri, FS; Sanz-Hernandez, M; Vendruscolo, M	1
Miyoshi, N; Nakamura, Y; Ohishi, T; Pervin, M; Tanabe, H; Unno, K	1
Chen, Z; Jiang, Z; Li, Y; Liu, L; Lu, Z; Qing, H; Yang, Q; Zhang, L; Zhang, X	1
Cao, S; Chen, L; Hu, X; Yang, J; Zhou, W	1
Cerboni, L; De Palma, A; Grandori, R; Konijnenberg, A; Legname, G; Mauri, P; Moons, R; Narkiewicz, J; Natalello, A; Ponzini, E; Rossi, R; Santambrogio, C; Sobott, F	1
Ding, L; Ding, Y; Teng, Y; Zhao, J; Zhou, P	1
Bolakhrif, N; Buell, AK; Haas, R; Peduzzo, A; Sternke-Hoffmann, R	1
Tang, Y; Wei, G; Yao, Y	1
Aguirre, C; Fujiwara, T; Goto, Y; Ikenaka, K; Kawata, Y; Kimura, Y; Mochizuki, H; So, M; Sugiki, T; Yamaguchi, K	1
Cordeiro, Y; Gonçalves, PB; Sodero, ACR	1
Jovcevski, B; Marty, MT; Pukala, TL; Sanders, HM	1
Kostelic, MM; Marty, MT; Sanders, HM; Zak, CK	1
Grønnemose, AL; Jørgensen, TJD; Otzen, DE; Østerlund, EC	1
Li, X; Tang, Y; Wei, G; Yang, Z; Yao, Y; Zhou, Y	1
Cordeiro, Y; Gonçalves, PB; Palhano, FL; Sodero, ACR	1

Reviews

3 review(s) available for epigallocatechin gallate and alpha-synuclein

Article	Year
Tea Polyphenols in Parkinson's Disease. Advances in experimental medicine and biology, 2015, Volume: 863 Topics: alpha-Synuclein; Antioxidants; Biflavonoids; Catechin; Humans; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Polyphenols; Tea	2015
Beneficial Effects of Green Tea Catechins on Neurodegenerative Diseases. Molecules (Basel, Switzerland), 2018, May-29, Volume: 23, Issue:6 Topics: alpha-Synuclein; Alzheimer Disease; Amyloid beta-Peptides; Camellia sinensis; Catechin; Cerebral Cortex; Humans; Molecular Docking Simulation; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Tea	2018
Green Tea Epigallocatechin-3-gallate (EGCG) Targeting Protein Misfolding in Drug Discovery for Neurodegenerative Diseases. Biomolecules, 2021, 05-20, Volume: 11, Issue:5 Topics: alpha-Synuclein; Alzheimer Disease; Amyloid beta-Protein Precursor; Catechin; Drug Discovery; Humans; Molecular Targeted Therapy; Neurodegenerative Diseases; Parkinson Disease; Protein Aggregates; Protein Folding; Tea	2021

Other Studies

39 other study(ies) available for epigallocatechin gallate and alpha-synuclein

Article	Year
Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate. Journal of molecular neuroscience : MN, 2004, Volume: 24, Issue:3 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Apomorphine; Catechin; Disease Models, Animal; Free Radicals; Iron; Iron Chelating Agents; Lewy Bodies; Male; Mice; Mice, Inbred C57BL; Nerve Tissue Proteins; Neuroprotective Agents; Oxidative Stress; Parkinsonian Disorders; Substantia Nigra; Synucleins; Ubiquitin	2004
A yeast-based model of alpha-synucleinopathy identifies compounds with therapeutic potential. Biochimica et biophysica acta, 2006, Volume: 1762, Issue:3 Topics: alpha-Synuclein; Brain Diseases; Caspase Inhibitors; Caspases; Catechin; Flavonoids; Humans; Metals; Models, Biological; Molecular Structure; Neuroprotective Agents; Recombinant Fusion Proteins; Risk Factors; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins	2006
EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nature structural & molecular biology, 2008, Volume: 15, Issue:6 Topics: alpha-Synuclein; Amyloid; Amyloid beta-Peptides; Amyloid Neuropathies; Catechin; Humans; Peptide Fragments; Plaque, Amyloid; Protein Binding	2008
Escaping amyloid fate. Nature structural & molecular biology, 2008, Volume: 15, Issue:6 Topics: alpha-Synuclein; Amyloid beta-Peptides; Amyloid Neuropathies; Catechin; Humans; Peptide Fragments; Plaque, Amyloid	2008
Residue Glu83 plays a major role in negatively regulating alpha-synuclein amyloid formation. Biochemical and biophysical research communications, 2010, Jan-15, Volume: 391, Issue:3 Topics: alpha-Synuclein; Amyloid; Catechin; Dopamine; Flavanones; Glutamic Acid; Humans; Mutation; Neurodegenerative Diseases; Neuroprotective Agents	2010
EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity. Proceedings of the National Academy of Sciences of the United States of America, 2010, Apr-27, Volume: 107, Issue:17 Topics: alpha-Synuclein; Amyloid; Amyloid beta-Peptides; Amyloid Neuropathies; Animals; Blotting, Western; Catechin; CHO Cells; Chromatography, Affinity; Circular Dichroism; Cricetinae; Cricetulus; Escherichia coli; Humans; Microscopy, Atomic Force; Microscopy, Electron, Transmission; Microscopy, Fluorescence; Neuroprotective Agents; PC12 Cells; Rats	2010
The flavanol (-)-epigallocatechin 3-gallate inhibits amyloid formation by islet amyloid polypeptide, disaggregates amyloid fibrils, and protects cultured cells against IAPP-induced toxicity. Biochemistry, 2010, Sep-21, Volume: 49, Issue:37 Topics: alpha-Synuclein; Amyloid; Amyloid beta-Protein Precursor; Animals; Benzothiazoles; Catechin; Cell Culture Techniques; Diabetes Mellitus, Type 2; Flavonoids; Islet Amyloid Polypeptide; Microscopy, Electron, Transmission; Phenols; Polyphenols; Protease Nexins; Rats; Receptors, Cell Surface; Thiazoles	2010
Amyloid formation and disaggregation of α-synuclein and its tandem repeat (α-TR). Biochemical and biophysical research communications, 2010, Oct-01, Volume: 400, Issue:4 Topics: alpha-Synuclein; Amyloid; Benzothiazoles; Catechin; Flavanones; Humans; Imidazoles; Imides; Ionic Liquids; Microscopy, Electron, Transmission; Parkinson Disease; Sulfonamides; Tandem Repeat Sequences; Thiazoles	2010
Black tea theaflavins inhibit formation of toxic amyloid-β and α-synuclein fibrils. Biochemistry, 2011, Dec-13, Volume: 50, Issue:49 Topics: alpha-Synuclein; Amyloid; Amyloid beta-Peptides; Animals; Antioxidants; Biflavonoids; Binding Sites; Camellia sinensis; Catechin; Cell Line, Tumor; Congo Red; Drug Evaluation, Preclinical; Fluorescence; Hydrophobic and Hydrophilic Interactions; Plaque, Amyloid; Protein Denaturation; Rats	2011
Rapid cytotoxicity screening platform for amyloid inhibitors using a membrane-potential sensitive fluorescent probe. Analytical chemistry, 2013, Jan-02, Volume: 85, Issue:1 Topics: alpha-Synuclein; Amyloid beta-Peptides; Antioxidants; Barbiturates; Biosensing Techniques; Catechin; Cell Line, Tumor; Cell Survival; Flavanones; Fluorescent Dyes; Humans; Isoxazoles; Peptide Fragments; Recombinant Proteins; Thiobarbiturates	2013
How epigallocatechin gallate can inhibit α-synuclein oligomer toxicity in vitro. The Journal of biological chemistry, 2014, Aug-01, Volume: 289, Issue:31 Topics: alpha-Synuclein; Biopolymers; Calorimetry, Differential Scanning; Catechin; Cell Membrane Permeability; Circular Dichroism; In Vitro Techniques; Microscopy, Confocal; Microscopy, Electron, Transmission; Nuclear Magnetic Resonance, Biomolecular; Protein Structure, Secondary	2014
Novel Epigenetic Regulation of Alpha-Synuclein Expression in Down Syndrome. Molecular neurobiology, 2016, Volume: 53, Issue:1 Topics: alpha-Synuclein; Animals; Catechin; Disease Models, Animal; DNA Methylation; Down Syndrome; Epigenesis, Genetic; Mice; Promoter Regions, Genetic	2016
Noninvasive bioluminescence imaging of α-synuclein oligomerization in mouse brain using split firefly luciferase reporters. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2014, Dec-03, Volume: 34, Issue:49 Topics: alpha-Synuclein; Animals; Catechin; Cell Death; Cells, Cultured; Corpus Striatum; Dopaminergic Neurons; Humans; Luciferases, Firefly; Luminescent Measurements; Mice; Neuroimaging; Neuroprotective Agents; Protein Aggregates; Substantia Nigra; Tacrolimus	2014
Tea polyphenols alleviate motor impairments, dopaminergic neuronal injury, and cerebral α-synuclein aggregation in MPTP-intoxicated parkinsonian monkeys. Neuroscience, 2015, Feb-12, Volume: 286 Topics: alpha-Synuclein; Animals; Catechin; Cell Survival; Corpus Striatum; Dopamine; Dopaminergic Neurons; Female; Macaca fascicularis; Motor Activity; Neuroprotective Agents; Parkinsonian Disorders; Substantia Nigra	2015
Au nanostructured surfaces for electrochemical and localized surface plasmon resonance-based monitoring of α-synuclein-small molecule interactions. ACS applied materials & interfaces, 2015, Feb-25, Volume: 7, Issue:7 Topics: alpha-Synuclein; Biosensing Techniques; Catechin; Copper; Electrochemistry; Gold; Metal Nanoparticles; Protein Binding; Surface Plasmon Resonance; Tin Compounds	2015
Quantitative thermophoretic study of disease-related protein aggregates. Scientific reports, 2016, Mar-17, Volume: 6 Topics: alpha-Synuclein; Calorimetry; Catechin; Fluorescent Dyes; Microscopy, Atomic Force; Protein Aggregates; Protein Binding; Static Electricity; Temperature	2016
Epigallocatechin Gallate (EGCG) Inhibits Alpha-Synuclein Aggregation: A Potential Agent for Parkinson's Disease. Neurochemical research, 2016, Volume: 41, Issue:10 Topics: alpha-Synuclein; Catechin; Cells, Cultured; Humans; Lewy Bodies; Parkinson Disease	2016
Opposite Structural Effects of Epigallocatechin-3-gallate and Dopamine Binding to α-Synuclein. Analytical chemistry, 2016, 09-06, Volume: 88, Issue:17 Topics: alpha-Synuclein; Binding Sites; Catechin; Dopamine; Molecular Structure; Nanotechnology; Spectrometry, Mass, Electrospray Ionization	2016
Potential for brain accessibility and analysis of stability of selected flavonoids in relation to neuroprotection in vitro. Brain research, 2016, 11-15, Volume: 1651 Topics: alpha-Synuclein; Animals; Anthocyanins; Antioxidants; Apoptosis; Brain; Catechin; Cells, Cultured; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Stability; Endothelial Cells; Flavonoids; Glucosides; Humans; Necrosis; Neurons; Neuroprotective Agents; Oxidative Stress; Protein Multimerization; Quercetin; Rats, Wistar; Recombinant Proteins	2016
Site-Specific Fluorescence Polarization for Studying the Disaggregation of α-Synuclein Fibrils by Small Molecules. Biochemistry, 2017, 02-07, Volume: 56, Issue:5 Topics: alpha-Synuclein; Amino Acid Sequence; Catechin; Dopamine; Fluorescence Polarization; Fluorescent Dyes; Humans; Masoprocol; Phosphatidylcholines; Protein Aggregates; Recombinant Proteins; Small Molecule Libraries; Sodium Dodecyl Sulfate; Unilamellar Liposomes; Xanthenes	2017
Polyphenols in combination with β-cyclodextrin can inhibit and disaggregate α-synuclein amyloids under cell mimicking conditions: A promising therapeutic alternative. Biochimica et biophysica acta. Proteins and proteomics, 2017, Volume: 1865, Issue:5 Topics: alpha-Synuclein; Amyloid; Amyloidogenic Proteins; Animals; beta-Cyclodextrins; Catechin; Cell Line; Cell Survival; Circular Dichroism; Curcumin; Humans; Mice; Parkinson Disease; Polyphenols; Protein Aggregation, Pathological	2017
An ortho-Iminoquinone Compound Reacts with Lysine Inhibiting Aggregation while Remodeling Mature Amyloid Fibrils. ACS chemical neuroscience, 2017, 08-16, Volume: 8, Issue:8 Topics: alpha-Synuclein; Amyloid beta-Peptides; Animals; Catechin; Cell Survival; Cells, Cultured; Chickens; Dopaminergic Neurons; HEK293 Cells; Humans; Lysine; Methionine; Mice; Micrococcus luteus; Microtubule-Associated Proteins; Muramidase; Neuroprotective Agents; Oxidation-Reduction; Peptide Fragments; Protein Aggregation, Pathological; Quinones; Tyrosine 3-Monooxygenase	2017
Influence of EGCG on α-synuclein (αS) aggregation and identification of their possible binding mode: A computational study using molecular dynamics simulation. Chemical biology & drug design, 2018, Volume: 91, Issue:1 Topics: alpha-Synuclein; Binding Sites; Catechin; Humans; Hydrogen Bonding; Molecular Dynamics Simulation; Protein Structure, Secondary; Protein Structure, Tertiary; Thermodynamics	2018
Metal chelator EGCG attenuates Fe(III)-induced conformational transition of α-synuclein and protects AS-PC12 cells against Fe(III)-induced death. Journal of neurochemistry, 2017, Volume: 143, Issue:1 Topics: alpha-Synuclein; Animals; Catechin; Cell Death; Cell Survival; Chelating Agents; Cytoprotection; Dose-Response Relationship, Drug; Ferric Compounds; PC12 Cells; Protein Conformation; Rats; Reactive Oxygen Species	2017
Comparison of α-Synuclein Fibril Inhibition by Four Different Amyloid Inhibitors. ACS chemical neuroscience, 2017, 12-20, Volume: 8, Issue:12 Topics: alpha-Synuclein; Amphotericin B; Amyloid; Binding Sites; Catechin; Dopamine; Kinetics; Neuroprotective Agents; Protein Binding	2017
EGCG-mediated Protection of the Membrane Disruption and Cytotoxicity Caused by the 'Active Oligomer' of α-Synuclein. Scientific reports, 2017, 12-20, Volume: 7, Issue:1 Topics: alpha-Synuclein; Amyloid; Animals; Catechin; Cell Membrane; Disease Models, Animal; Drosophila melanogaster; Electrophoresis, Polyacrylamide Gel; Microscopy, Electron, Transmission; Parkinson Disease	2017
Molecular determinants of the interaction of EGCG with ordered and disordered proteins. Biopolymers, 2018, Volume: 109, Issue:10 Topics: alpha-Synuclein; Catechin; Humans; Intrinsically Disordered Proteins; Muramidase; Protein Binding	2018
"Cell-addictive" dual-target traceable nanodrug for Parkinson's disease treatment via flotillins pathway. Theranostics, 2018, Volume: 8, Issue:19 Topics: alpha-Synuclein; Animals; Animals, Genetically Modified; Catechin; Cell Line; Disease Models, Animal; Dopaminergic Neurons; Drug Carriers; Humans; Membrane Proteins; Mice; Molecular Targeted Therapy; Nanoparticles; Neuroprotective Agents; Parkinson Disease; Protein Aggregation, Pathological; Treatment Outcome	2018
Effects and mechanism of epigallocatechin-3-gallate on apoptosis and mTOR/AKT/GSK-3β pathway in substantia nigra neurons in Parkinson rats. Neuroreport, 2019, 01-16, Volume: 30, Issue:2 Topics: alpha-Synuclein; Animals; Apoptosis; Catechin; Glycogen Synthase Kinase 3 beta; Male; Neuroprotective Agents; Parkinsonian Disorders; Proto-Oncogene Proteins c-akt; Rats; Signal Transduction; Substantia Nigra; TOR Serine-Threonine Kinases; Treatment Outcome	2019
Methionine oxidation in α-synuclein inhibits its propensity for ordered secondary structure. The Journal of biological chemistry, 2019, 04-05, Volume: 294, Issue:14 Topics: alpha-Synuclein; Catechin; Humans; Lewy Bodies; Methionine; Oxidation-Reduction; Parkinson Disease; Protein Aggregates; Protein Folding; Protein Structure, Secondary; Protein Structure, Tertiary	2019
Complex of EGCG with Cu(II) Suppresses Amyloid Aggregation and Cu(II)-Induced Cytotoxicity of α-Synuclein. Molecules (Basel, Switzerland), 2019, Aug-14, Volume: 24, Issue:16 Topics: alpha-Synuclein; Amyloidogenic Proteins; Animals; Catechin; Cell Line; Copper; Neuroprotective Agents; Nuclear Magnetic Resonance, Biomolecular; Oxidative Stress; Parkinson Disease; Protein Aggregates; Protein Aggregation, Pathological; Rats; Reactive Oxygen Species	2019
The Aggregation Conditions Define Whether EGCG is an Inhibitor or Enhancer of International journal of molecular sciences, 2020, Mar-14, Volume: 21, Issue:6 Topics: alpha-Synuclein; Amyloid; Catechin; Humans; Parkinson Disease; Protein Aggregates; Protein Aggregation, Pathological	2020
Epigallocatechin Gallate Destabilizes α-Synuclein Fibril by Disrupting the E46-K80 Salt-Bridge and Inter-protofibril Interface. ACS chemical neuroscience, 2020, 12-16, Volume: 11, Issue:24 Topics: alpha-Synuclein; Catechin; Humans; Lewy Bodies; Parkinson Disease	2020
Polyphenol-solubility alters amyloid fibril formation of α-synuclein. Protein science : a publication of the Protein Society, 2021, Volume: 30, Issue:8 Topics: alpha-Synuclein; Amyloid; Amyloidogenic Proteins; Catechin; Magnetic Resonance Spectroscopy; Polyphenols; Protein Conformation; Solubility	2021
Structural and mechanistic insights into amyloid-β and α-synuclein fibril formation and polyphenol inhibitor efficacy in phospholipid bilayers. The FEBS journal, 2022, Volume: 289, Issue:1 Topics: alpha-Synuclein; Amyloid; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloidogenic Proteins; Catechin; Humans; Lipid Bilayers; Membrane Lipids; Parkinson Disease; Phospholipids; Polyphenols	2022
Lipids and EGCG Affect α-Synuclein Association and Disruption of Nanodiscs. Biochemistry, 2022, 06-07, Volume: 61, Issue:11 Topics: alpha-Synuclein; Catechin; Glycerol; Lipid Bilayers; Lipids	2022
EGCG has Dual and Opposing Effects on the N-terminal Region of Self-associating α-synuclein Oligomers. Journal of molecular biology, 2022, 12-15, Volume: 434, Issue:23 Topics: alpha-Synuclein; Catechin; Humans; Oxidation-Reduction; Parkinson Disease; Protein Conformation; Protein Folding	2022
EGCG attenuates α-synuclein protofibril-membrane interactions and disrupts the protofibril. International journal of biological macromolecules, 2023, Mar-01, Volume: 230 Topics: alpha-Synuclein; Catechin; Humans; Membranes; Parkinson Disease	2023
How oxidized EGCG remodels α-synuclein fibrils into non-toxic aggregates: insights from computational simulations. Physical chemistry chemical physics : PCCP, 2023, Jul-19, Volume: 25, Issue:28 Topics: alpha-Synuclein; Amyloid; Amyloidogenic Proteins; Catechin; Humans; Parkinson Disease; Protein Aggregates	2023